• Mumbai
  • 3 May 2013
  • News
  • By Manasi

"We need a stonger Pharmacovigilance program" says deputy DCGI

Dr.V G Somani, Deputy DCGI opined at a recently organized Biosimilar conference, that increased pharmacovigilance data from the Indian industry is the need of the hour


Parminder Kaur, owner, Regulatory Affairs and PhV consultant, RegPak BioPharma Consulting; Dr. V.G Somani, Deputy Drugs Controller India; Bobby George, assistant vice president and head Regulatory Affairs, Reliance Life Sciences; Yasmin Shenoy. director- Regulatory Affairs, Sanofi Aventis,at the panel discussion on Indian biosimilar regulations and the regulatory challenges in the Asian biosimilar market today, at the 3rd Biosimilars Congregation 2013 in Mumbai

At the recently organized 3rd Biosimilar Congregation 2013, the challenges involved in the development of biosimilars were brought to center stage, allowing industry professionals, regulators and legal experts to share their views.

Dr. V.G Somani, Deputy Drugs Controller India was positive about the scope of biosimilars in India. He said, "India has a good capability in the field of biosimilars as well as a good market, since most innovative molecules are out of reach for the common man. The real challenge in giving approvals for biosimilars is that there is no data from innovator companies available in the country for reference molecules . This makes things very difficult, from a regulatory point of view. Whether we compare it with the actual reference molecule or the Indian reference, things like these present difficulties."

When asked what he expects from the drug industry he replied," What we need today is a strong  and focused Pharmacovigilance program. This is extremely important from a patient perspective. We are not active about Pharmacovigilance and doctors have been passive about this issue as well. Those you develop a product sould take the onus of gathering information about it as well."

One of the leading companies in the biosimilar space has been the biopharmaceutical firm, Reliance Life Sciences. About the market for biosimilars, Bobby George, assitant vice president and head, Regulatory Affairs, Reliance Life Sciences said, "RLS currently has 7 biosimilars in the market with few others in clinical development.Overall. the biosimilar sector has shown a healthy growth. there are approximately 55 players in this market, overall. However there are very few manufacturers in this space, a lot of them import the products."

The conferences featured a number of experienced professionals in the biosimilars space, talk about different aspects related to the development and marketing of biosimilars in not just Indian markets but also the US and EU ones. The talk on Indian biosimilar regulations featured Yasmin Shenoy, director, Regulatory Affairs, Sanofi Aventis as well who said, "Even though Sanofi is known worldwide as an innovator company, we are open to biosimilars as well, Shantha Biotechnics is a perfect example of that."


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email